A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lpathomab Administered Intravenously to Healthy Volunteers

Trial Profile

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Lpathomab Administered Intravenously to Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2016

At a glance

  • Drugs Lpathomab (Primary)
  • Indications Neuropathic pain
  • Focus Adverse reactions; First in man
  • Sponsors Lpath
  • Most Recent Events

    • 19 Apr 2016 Results published in an Lpath media release.
    • 19 Apr 2016 Status changed from active, no longer recruiting to completed, according to an Lpath media release.
    • 12 Feb 2016 Time frame for primary endpoint has been changed from 29 days to 85 days as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top